The management of T2D has reached an era in which therapies now have core metabolic actions regardless of glycemic control, i.e., remarkable weight loss and cardiorenal protection with GLP-1 RAs, SGLT2 inhibitors, and the dual agonist tirzepatide. This evidence concerns the gene GCG and type 2 diabetes mellitus.